Navidea Biopharmaceuticals NAVB today
announced that the U.S. Patent and Trademark Office (USPTO) has issued a
new patent covering the formulation of the Company's radiolabeled
dopamine transporter (DAT) receptor ligand, NAV5001, used with SPECT
imaging for potential differential diagnosis of Parkinsonian Syndromes
and Dementia with Lewy Bodies. The patent (8,574,545) is set to expire
in 2031.
The new U.S. patent, “Labeled Iodinated Tropane Formulation,” extends
the scope and longevity of the NAV5001 intellectual property (IP)
portfolio. The high concentration formulation protected by this patent
may afford greater commercial flexibility and manufacturing efficiency
to optimize distribution. Navidea anticipates commencing
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in